Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer

Revista da Associação Médica Brasileira

Rafael Malagoli Rocha²  Cristiana Buzelin Nunes¹  Fernanda Squarcio Fernandes Sanches¹  Gislene Fátima Silva Rocha¹  Flávio Nepomuceno De Oliveira¹  Jorge Sérgio Reis-filho¹  Maryou B. Lambros¹  Helenice Gobbi¹ 

[1] ,UFMGBelo Horizonte MG ,Brasil

关键词: Monoclonal antibodies;    Immunohistochemistry;    Breast neoplasms;    hormone receptors;    HER2;    Anticorpos monoclonais;    Imunoistoquímica;    Neoplasia de mama;    Receptores hormonais;    HER2;   

DOI  :  10.1590/S0104-42302009000200020

来源: SciELO

【 摘 要 】

BACKGROUND: Novel rabbit monoclonal antibodies (RabMab) for estrogen (ER), progesterone (PR) receptors and HER2 evaluation by immunohistochemistry have recently been commercially released. We compared the RabMab anti-ER, anti-PR and anti-HER2 to mouse monoclonal antibodies (Mab) using tissue microarrays (TMA) of breast carcinomas. METHODS: Two TMA containing breast carcinomas were built. Sections were immunostained using anti-ER and anti-PR, Mab and RabMab. The sections stained for ER and PR were evaluated considering positive those tumors in which more than 1% of the tumor cell nuclei stained moderate or strong. For HER2, the immunostained sections were evaluated using the ASCO/CAP guidelines for HER2. Chromogenic in situ hybridization (CISH) was used as the gold standard for HER2 evaluation. CISH was evaluated using the Zymed HER2 CISH interpretation guidelines. RESULTS: RabMab against ER have similar staining patterns compared to the 6F11 (Mab), but stronger than 1D5 (Mab) from three different suppliers. The RabMab against PR provide stronger and sharper immunohistochemical signals compared to Mab. The detection of HER2 protein overexpression was more prevalent with the polyclonal antibodies and RabMab than with the Mab. These were more specific than the RabMab, which were more sensitive when compared to CISH. CONCLUSION: The novel RabMab against ER and PR showed higher intensity of staining than the Mab. The RabMab against HER2 is more sensitive than Mab, however, Mab presented more specificity than RabMab when compared to CISH for HER2 evaluation of breast carcinomas.

【 授权许可】

CC BY-NC   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License